NurExone Appoints Biotech Industry Leader – Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
By GlobeNewswire Published on April 23, 2025, 01:05 IST
TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. ('Exo-Top'), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top is a U.S.-based GMP-compliant exosome manufacturing site and will be the pillar of the Company's global supply chain and commercialization strategy.
Mr. Licht's new roles will include leading the establishment of Exo-Top's manufacturing capabilities, developing strategic partnerships, and developing corporate initiatives aligned with NurExone's path toward clinical readiness and future fundraising.
'Jacob's appointment underscores our commitment to operational excellence and financial growth in the U.S. market,' said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. 'Exo-Top is expected to be integral to scaling our manufacturing capacity, building robust quality systems, and supporting our progress towards human clinical trials and commercialization.'
Yoram Drucker, Chairman of NurExone, stated: 'Exo-Top will serve as the cornerstone of our exosome production in the U.S., and Jacob is the right executive to lead it. His track record in scaling biotech operations, executing transformative deals, and his business acumen aligns perfectly with our financial strategy as we scale to grow revenue and expand our North America footprint.'
Mr. Licht brings more than 20 years of experience in manufacturing-intensive biotech and specialty pharmaceuticals companies. He has led transactions totaling $1 billion across mergers and acquisitions, licensing, and asset sales. His previous leadership roles include Vice President of Business Development at Lantheus Medical Imaging and Vice President of Corporate Development at Bavarian Nordic and Emergent BioSolutions, where he was instrumental in driving strategic acquisitions and commercial partnerships.
'NurExone's platform has the potential to transform how we treat Central Nerve Injuries in multiple indications,' said Jacob Licht. 'The leadership team is exceptional, and with Exo-Top, we're building the infrastructure to support global production, operational independence, and long-term value creation.'
Continuance into Ontario
The Company is also pleased to announce that effective today, further to its press release dated June 4, 2024, it has completed a continuance from the Province of Alberta governed under the Business Corporations Act (Alberta) into the Province of Ontario governed under the Business Corporations Act (Ontario) (the 'Continuance'). The Continuance was approved by the Company's shareholders at its annual general and special meeting held on Monday, June 3, 2024.
About NurExone
NurExone Biologic Inc. is a TSX Venture Exchange ('TSXV'), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets i . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone? , visit www.nurexone.com or follow NurExone on LinkedIn , Twitter , Facebook , or YouTube .
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034
Email: [email protected]
Oak Hill Financial Inc.2 Bloor Street, Suite 2900Toronto, Ontario M4W 3E2
Investor Relations – Canada Phone: +1-647-479-5803
Email: [email protected]
Dr. Eva Reuter
Investor Relations – GermanyPhone: +49-69-1532-5857
Email: [email protected]
Allele Capital Partners
Investor Relations – U.S.Phone: +1 978-857-5075
Email: [email protected]
FORWARD-LOOKING STATEMENTS
This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: Mr. Licht's roles within the Company and Exo-Top; Exo-Top will serve as the cornerstone of the Company's exosome production in the U.S.; Exo-Top will be the pillar of the Company's global supply chain and commercialization strategy; the Company advancing towards clinical and commercial breakthroughs in regenerative medicine; the Company's current expectations regarding future development plans, operational initiatives, and strategic objectives; the advancement of the Company's therapeutic programs and clinical milestones; the expansion of infrastructure; potential commercial opportunities; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company realizing on the benefits of exosomes; the Company will produce and supply exosomes for a wide range of applications; the ability of the Company's products to be used for patient treatment; the Company fulfilling its intended future plans and expectations; the Company maintaining its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and cell therapy applications; the Company will receive all regulatory approvals; the Company will have clinical and commercial breakthroughs in regenerative medicine; the Company will be able to realize its future development plans, operational initiatives, and strategic objectives; the Company's ability to advance its therapeutic programs and clinical milestones; the expansion of infrastructure; potential commercial opportunities; Mr. Licht will have the ability to be the Chief Executive Officer of Exo-Top and Vice President, Corporate Development of the Company and will perform the roles as set herein; Exo-Top will have the ability to serve as the cornerstone of the Company's exosome production in the U.S.; Exo-Top will be the pillar of the Company's global supply chain and commercialization strategy; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, including Mr. Licht; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the inability of the Company to collaborate with pharma companies; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not expand its infrastructure; no commercial opportunities for the Company to capitalize on; Mr. Licht will not perform the roles as set out herein; Exo-Top will not serve as the cornerstone of the Company's exosome production in the U.S.; Exo-Top will not be the pillar of the Company's global supply chain and commercialization strategy; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury , Glaucoma
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Lineage, Inc. Declares Dividend for Second Quarter 2025
NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announced that its Board of Directors has declared a cash dividend of $0.5275 per share for the second quarter of 2025. The dividend will be paid on July 21, 2025, to shareholders of record of the Company's common stock as of the close of business on June 30, 2025. About Lineage Lineage, Inc. (NASDAQ: LINE) is the world's largest global temperature-controlled warehouse REIT with a network of over 485 strategically located facilities totaling approximately 86 million square feet and approximately 3.1 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world's largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at and join us on LinkedIn, Facebook, Instagram, and X. Forward-Looking Statements Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage's use of forward-looking terminology such as 'may,' 'will,' 'expect,' 'intend,' 'anticipate,' 'estimate,' 'believe,' 'continue,' 'seek,' 'objective,' 'goal,' 'strategy,' 'plan,' 'focus,' 'priority,' 'should,' 'could,' 'potential,' 'possible,' 'look forward,' 'optimistic,' or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage's performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.
Business Wire
2 hours ago
- Business Wire
Orion Properties Inc. Confirms Receipt of Unsolicited Non-Binding Indication of Interest from Kawa Capital Management
PHOENIX--(BUSINESS WIRE)--Orion Properties Inc. (NYSE: ONL) ('Orion' or the 'Company') confirmed its receipt today of an unsolicited, non-binding indication of interest from Kawa Capital Management, Inc. ('Kawa') to potentially acquire all of the outstanding shares of common stock of the Company not already owned by Kawa for cash consideration of $2.50 per share. Kawa currently beneficially owns 5,474,027 of the outstanding shares of the Company's common stock, or approximately 9.7%, based on its most recent Schedule 13D filing dated June 20, 2025. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, Orion's Board of Directors will carefully review and evaluate the unsolicited indication of interest to determine the course of action that it believes is in the best interests of the Company and all Orion shareholders. Orion does not intend to comment further on Kawa's unsolicited indication of interest until the Board has completed its review. Orion shareholders do not need to take any action at this time. About Orion Properties Inc. Orion Properties Inc. is an internally-managed real estate investment trust engaged in the ownership, acquisition and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased primarily on a single-tenant net lease basis to creditworthy tenants. The Company's portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory and R&D and flex/industrial properties. The Company was founded on July 1, 2021, spun-off from Realty Income (NYSE: O) on November 12, 2021 and began trading on the New York Stock Exchange on November 15, 2021. The Company is headquartered in Phoenix, Arizona and has an office in New York, New York. For additional information on the Company and its properties, please visit Forward-Looking Statements Information set forth in this press release includes 'forward-looking statements' which reflect the Company's expectations and projections regarding future events and plans and future financial condition. Such forward-looking statements include statements regarding the evaluation by the Orion Board of Directors of the Kawa proposal. These forward-looking statements are based on information currently available to the Company and involve a number of known and unknown assumptions and risks, uncertainties and other factors, which may be difficult to predict and beyond the Company's control, that could cause actual events and plans or could cause the Company's business, financial condition, liquidity and results of operations to differ materially from those expressed or implied in the forward-looking statements. Factors that may affect future results include: the Company's actions taken or contemplated to enhance its long-term prospects and create value for its shareholders; the risk of rising interest rates, such as that our borrowing costs may increase and we may be unable to refinance our debt obligations on favorable terms and in a timely manner or at all; conditions associated with the global market, including an oversupply of office space, tenant credit risk and general economic conditions; the extent to which changes in workplace practices and office space utilization, including remote and hybrid work arrangements, and changes in governmental budgetary priorities, will continue and the impact that may have on demand for office space at our properties; our ability to comply with the terms of our credit agreement; changes in the real estate industry and in the performance of financial markets and interest rates and our ability to effectively hedge against interest changes; and our ability to renew leases with existing tenants or re-let vacant space to new tenants on favorable terms and in a timely manner or at all. Additional factors that may affect future results are contained in the Company's filings with the Securities and Exchange Commission ('SEC'), which are available at the SEC's website at The Company disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of changes in underlying assumptions or factors, new information, future events or otherwise, except as required by law.
